Charles River And PathoQuest Announce Publication Of A Head-To-Head Study Validating Proprietary Next Generation Sequencing Viral Safety Assay As A Reliable In Vitro Alternative To Animal Testing Methods
Portfolio Pulse from Happy Mohamed
Charles River Laboratories International, Inc. (NYSE:CRL) and PathoQuest SAS have published a study validating their Next Generation Sequencing (NGS) viral safety assay as a reliable alternative to animal testing methods. The study demonstrated that the NGS-based assay had a greater capability of detecting viral contaminants compared to in vivo assays. The results support the use of the evaluated NGS-based transcriptomic assay as a superior alternative to current in vivo testing methods and aligns with the proposed ICH Q5A(R2) guidelines which are anticipated to be finalized and implemented by the end of 2023.
September 06, 2023 | 12:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Charles River Laboratories' partnership with PathoQuest and the successful validation of their NGS viral safety assay could potentially boost the company's reputation and market position. The alignment of their product with upcoming ICH Q5A(R2) guidelines could also provide a competitive advantage.
The successful validation of Charles River Laboratories' NGS viral safety assay, developed in partnership with PathoQuest, could enhance the company's reputation and market position. The fact that their product aligns with the upcoming ICH Q5A(R2) guidelines could provide a competitive advantage, as it demonstrates the company's commitment to adhering to regulatory standards and advancing scientific knowledge. This could potentially lead to increased demand for their product, positively impacting their stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100